• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form DEFA14A filed by Lineage Cell Therapeutics Inc.

    6/11/25 5:00:06 PM ET
    $LCTX
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care
    Get the next $LCTX alert in real time by email
    DEFA14A 1 lctx_proxy_2025_-_ma_bt_.htm DEFA14A DEFA14A

    UNITED STATES

    SECURITIES AND EXCHANGE COMMISSION

    WASHINGTON, D.C. 20549

    Schedule 14A Information

    Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934

    Filed by the Registrant ☒

    Filed by a Party other than the Registrant ☐

    Check the appropriate box:

    ☐

    Preliminary Proxy Statement

    ☐

    Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2))

    ☐

    Definitive Proxy Statement

    ☒

    Definitive Additional Materials

    ☐

    Soliciting Material Pursuant to §240.14a-12

    Lineage Cell Therapeutics, Inc.

    (Name of Registrant as Specified in Its Charter)

    (Name of Person(s) Filing Proxy Statement if other than the Registrant)

    Payment of Filing Fee (Check the appropriate box):

    ☒

    No fee required.

    ☐

    Fee paid previously with preliminary materials.

    ☐

    Fee computed on table in exhibit required by Item 25(b) per Exchange Act Rules 14a-6(i)(1) and 0-11



    SUPPLEMENT TO THE PROXY STATEMENT

    FOR THE 2025 ANNUAL MEETING OF SHAREHOLDERS

    TO BE HELD ON JUNE 26, 2025

    This supplement (this “Supplement”) to the proxy statement of Lineage Cell Therapeutics, Inc. (“Lineage,” “we,” “us” and “our”), filed with the Securities and Exchange Commission (the “SEC”) on April 29, 2025 (the “proxy Statement”), is being furnished to our shareholders in connection with the solicitation of proxies by our Board of Directors (“Board”) for use at our 2025 annual meeting of shareholders (the “Meeting”) to be held at 2173 Salk Avenue, Suite 200, Carlsbad, CA 92008 on June 26, 2025 at 8:00 a.m. Pacific Time, including any adjournment or postponement thereof. This Supplement, dated June 11, 2025, is being filed with the SEC and is being made available to shareholders on or about June 11, 2025.

    Other than as set forth below, this Supplement does not modify or supplement the Proxy Statement in any manner. This Supplement should be read together with the Proxy Statement, each of which contains information that is important to your decisions in voting at the Annual Meeting.

    _______________________

    As disclosed in the Proxy Statement, the Audit Committee of our Board (the “Audit Committee”) selected Moss Adams LLP (“Moss Adams”) to serve as our independent registered public accounting firm for the fiscal year ending December 31, 2025.

    On June 3, 2025, we were notified that Moss Adams merged with Baker Tilly US, LLP (“Baker Tilly”), effective on June 3, 2025, and that the combined audit practices operate as Baker Tilly. In connection with the notification of the merger, Moss Adams resigned as our independent registered public accounting firm and the Audit Committee approved the appointment of Baker Tilly, as the successor to Moss Adams, as our independent registered public accounting firm for the fiscal year ending December 31, 2025.

    As reported in the Current Report on Form 8-K we filed with the SEC on June 9, 2025 (the “Auditor Change 8-K”), the audit report of Moss Adams on our consolidated financial statements for the year ended December 31, 2024, did not contain an adverse opinion or a disclaimer of opinion, and was not qualified or modified as to uncertainty, audit scope or accounting principles. During the year ended December 31, 2024, and from December 31, 2024 through June 3, 2025, there were no (i) disagreements (as defined in Item 304(a)(1)(iv) of Regulation S-K and the related instructions to Item 304 of Regulation S-K) between us and Moss Adams on any matter of accounting principles or practices, financial statement disclosure, or auditing scope or procedure, which disagreements, if not resolved to the satisfaction of Moss Adams, would have caused Moss Adams to make reference to the subject matter of such disagreements in connection with its report, or (ii) “reportable events,” as described in Item 304(a)(1)(v) of Regulation S-K, that would require disclosure under Item 304(a)(1)(v) of Regulation S-K.

    During our two most recent fiscal years and from December 31, 2024 through June 3, 2025, neither we, nor any person acting on our behalf, consulted Baker Tilly regarding (i) the application of accounting principles to a specified transaction, either completed or proposed, (ii) the type of the audit opinion that might be rendered on our financial statements, and Baker Tilly did not provide any written report or oral advice to us that Baker Tilly concluded was an important factor considered by us in reaching a decision as to the accounting, auditing or financial reporting issue, or (iii) any matter that was either the subject of a disagreement (as defined in Item 304(a)(1)(iv) of Regulation S-K and the related instructions to Item 304 of Regulation S-K) or a reportable event of the type described in Item 304(a)(1)(v) of Regulation S-K.

    We furnished Moss Adams with a copy of the disclosure in Item 4.01 of the Auditor Change 8-K and requested that Moss Adams furnish us with a letter addressed to the SEC stating whether Moss Adams agrees with the statements made by us in such Item 4.01, and if not, stating the respects in which it does not agree. Moss Adams furnished such a letter, a copy of which is filed as Exhibit 16.1 to the Auditor Change 8-K.

    As a result of the foregoing, with respect to Proposal 2 described in the Proxy Statement (the “Auditor Ratification Proposal”), our Board is requesting that our shareholders ratify the appointment of Baker Tilly as our independent registered public accounting firm for the fiscal year ending December 31, 2025, and our Board unanimously recommends you vote “FOR” the ratification of the appointment of Baker Tilly as our independent registered public accounting firm for the fiscal year ending December 31, 2025.

    All references to the ratification of the appointment of Moss Adams as our independent registered public accounting firm in the Proxy Statement are hereby updated to refer to the ratification of the appointment of Baker Tilly as our independent registered public accounting firm.

    We expect that a representative of Baker Tilly will be present at the Meeting, in person or by phone, and will have an opportunity to make a statement if he or she so desires and may respond to appropriate questions from shareholders.

    Important Voting Information

    Proxy cards and voting instructions previously returned by stockholders and votes previously cast by shareholders will remain valid and will be used at the Meeting unless changed or revoked. We will consider votes “FOR” or “AGAINST” the Auditor Ratification Proposal as votes “FOR” or “AGAINST,” respectively, the ratification of the appointment of Baker Tilly, as the successor accounting


    firm following the merger with Moss Adams, as our independent registered public accounting firm for the fiscal year ending December 31, 2025. Similarly, we will consider abstentions on the Auditor Ratification Proposal as abstentions on the vote to ratify the appointment of Baker Tilly as our independent registered public accounting firm for the fiscal year ending December 31, 2025.

    If you have already voted, submitted voting instructions or returned your proxy card, you do not need take any action unless you would like to change or revoke your prior vote, voting instructions or proxy card. Information regarding how to vote your shares and how to change or revoke your prior vote, voting instructions or proxy card is in the Proxy Statement.

     


    Get the next $LCTX alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $LCTX

    DatePrice TargetRatingAnalyst
    8/20/2024$4.00Buy
    Craig Hallum
    11/2/2022$5.00Outperform
    Robert W. Baird
    6/14/2022$4.00Buy
    B. Riley Securities
    8/19/2021$8.00Outperform
    Noble Capital Markets
    More analyst ratings

    $LCTX
    SEC Filings

    View All

    Lineage Cell Therapeutics Inc. filed SEC Form 8-K: Other Events

    8-K - Lineage Cell Therapeutics, Inc. (0000876343) (Filer)

    11/28/25 4:05:24 PM ET
    $LCTX
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Lineage Cell Therapeutics Inc. filed SEC Form 8-K: Other Events

    8-K - Lineage Cell Therapeutics, Inc. (0000876343) (Filer)

    11/24/25 6:49:07 AM ET
    $LCTX
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Lineage Cell Therapeutics Inc. filed SEC Form 8-K: Other Events

    8-K - Lineage Cell Therapeutics, Inc. (0000876343) (Filer)

    11/12/25 9:25:41 AM ET
    $LCTX
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $LCTX
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Lineage Takes Delivery of Gene-edited Hypoimmune Cell Line Under Partnership With Factor Bioscience

    Lineage Cell Therapeutics, Inc. (NYSE American and TASE: LCTX), a clinical-stage biotechnology company developing novel allogeneic, or "off the shelf," cell therapies for serious medical conditions, today announced the receipt of a novel, induced pluripotent stem cell (iPSC) line containing hypoimmunity edits, from Factor Bioscience Inc. ("Factor"). Generation of the line marks a successful milestone in the strategic collaboration between the two companies, under which Factor developed a proprietary, genetically engineered iPSC line that Lineage can utilize for differentiation into certain cell transplant product candidates. The novel cell line contains edits which are expected to support n

    1/6/26 8:00:00 AM ET
    $LCTX
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Lineage Cell Therapeutics Issues Letter to Stockholders

    Lineage Cell Therapeutics, Inc. (NYSE American and TASE: LCTX), a clinical-stage biotechnology company developing novel allogeneic, or "off the shelf," cell therapies for serious medical conditions, today published a letter to shareholders highlighting the company's achievements throughout 2025 and its corporate outlook for 2026. To Our Shareholders: As we conclude a successful 2025, I want to extend my appreciation for your continued support of Lineage Cell Therapeutics and our mission to pioneer the emerging field of allogeneic cell therapy. I also wish to provide an outline for how we plan to continue our success in 2026. The field of cell therapy has revolutionized oncology, savin

    1/5/26 8:00:00 AM ET
    $LCTX
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Beyond Insulin Pumps: Cell Therapies Unlock a $403B Cure Economy

    Issued on behalf of Avant Technologies Inc. Equity Insider News Commentary VANCOUVER, BC, Dec. 16, 2025 /PRNewswire/ -- The cell therapy manufacturing sector reached a pivotal inflection point in late 2025, with contract development and manufacturing organizations capturing 67.5% market share as the industry transitions from boutique R&D operations to scalable bioprocessing infrastructure[1]. Gene and CAR-T therapy demand has driven CDMO partnerships to expand viral vector production and GMP-compliant facilities at unprecedented velocity, overcoming bottlenecks that previously constrained commercial access[2]. Five companies positioned at this manufacturing convergence point are attracting i

    12/16/25 11:53:00 AM ET
    $BCLI
    $LCTX
    $MESO
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $LCTX
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Craig Hallum initiated coverage on Lineage Cell Therapeutics with a new price target

    Craig Hallum initiated coverage of Lineage Cell Therapeutics with a rating of Buy and set a new price target of $4.00

    8/20/24 8:32:59 AM ET
    $LCTX
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Robert W. Baird initiated coverage on Lineage Cell Therapeutics with a new price target

    Robert W. Baird initiated coverage of Lineage Cell Therapeutics with a rating of Outperform and set a new price target of $5.00

    11/2/22 6:28:33 AM ET
    $LCTX
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    B. Riley Securities initiated coverage on Lineage Cell Therapeutics with a new price target

    B. Riley Securities initiated coverage of Lineage Cell Therapeutics with a rating of Buy and set a new price target of $4.00

    6/14/22 7:59:45 AM ET
    $LCTX
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $LCTX
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Director Broadwood Partners, L.P. bought $6,000,000 worth of shares (7,894,737 units at $0.76) (SEC Form 4)

    4 - Lineage Cell Therapeutics, Inc. (0000876343) (Issuer)

    1/28/25 7:49:41 PM ET
    $LCTX
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Chief Financial Officer Howe Jill Ann bought $8,850 worth of shares (15,000 units at $0.59), increasing direct ownership by 143% to 25,500 units (SEC Form 4)

    4 - Lineage Cell Therapeutics, Inc. (0000876343) (Issuer)

    11/26/24 4:58:31 PM ET
    $LCTX
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    General Counsel Samuel George A. Iii bought $9,000 worth of shares (15,000 units at $0.60), increasing direct ownership by 209% to 22,184 units (SEC Form 4)

    4 - Lineage Cell Therapeutics, Inc. (0000876343) (Issuer)

    11/26/24 4:55:46 PM ET
    $LCTX
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $LCTX
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    President and CEO Culley Brian M was granted 8,925 shares and covered exercise/tax liability with 334 shares, increasing direct ownership by 4% to 222,135 units (SEC Form 4)

    4 - Lineage Cell Therapeutics, Inc. (0000876343) (Issuer)

    12/19/25 9:55:05 PM ET
    $LCTX
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    General Counsel and Secretary Samuel George A. Iii was granted 1,735 shares and covered exercise/tax liability with 65 shares, increasing direct ownership by 6% to 27,490 units (SEC Form 4)

    4 - Lineage Cell Therapeutics, Inc. (0000876343) (Issuer)

    12/19/25 9:55:03 PM ET
    $LCTX
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    SEC Form 4 filed by Director Bradsher Neal C

    4 - Lineage Cell Therapeutics, Inc. (0000876343) (Issuer)

    7/3/25 2:45:11 PM ET
    $LCTX
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $LCTX
    Financials

    Live finance-specific insights

    View All

    Lineage Cell Therapeutics Reports Third Quarter 2025 Financial Results and Provides Business Update

    Positive RG6501 (OpRegen®) Phase 1/2a Clinical Study 36 Month Results Featured at Clinical Trials at the Summit 2025 Entered Collaboration with William Demant Invest to Develop ReSonance™ (ANP1) for Sensorineural Hearing Loss Initiated Manufacturing Scale Project in Type 1 Diabetes Cell Therapy Lineage Cell Therapeutics, Inc. (NYSE American and TASE: LCTX), a clinical-stage biotechnology company developing novel allogeneic, or "off the shelf", cell therapies for serious medical conditions, today reported its third quarter 2025 financial and operating results and will host a conference call today at 4:30 p.m. Eastern Time to discuss these results and provide a business update. "It ha

    11/6/25 4:01:00 PM ET
    $LCTX
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Lineage Cell Therapeutics to Report Third Quarter 2025 Financial Results and Provide Business Update on November 6, 2025

    Lineage Cell Therapeutics, Inc. (NYSE American and TASE: LCTX), a clinical-stage biotechnology company developing allogeneic, or "off the shelf", cell therapies for serious medical conditions, today announced that it will report its third quarter 2025 financial and operating results on Thursday, November 6, 2025, following the close of the U.S. financial markets. Lineage management will also host a conference call and webcast on Thursday, November 6, 2025, at 4:30 p.m. Eastern Time/1:30 p.m. Pacific Time to discuss its third quarter 2025 financial and operating results and to provide a business update. Conference Call and Webcast Interested parties may access the conference call on Nove

    10/30/25 8:00:00 AM ET
    $LCTX
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Lineage Cell Therapeutics Reports Second Quarter 2025 Financial Results and Provides Business Update

    Positive RG6501 (OpRegen®) Phase 1/2a Clinical Study 36 Month Results Featured at Clinical Trials at the Summit 2025 Successfully Reduced-to-Practice Critical Aspect of Commercial-Scale, Cell-Based, GMP Production Processes First Chronic Patient Treated in New Clinical Study of OPC1 in Patients with Subacute and Chronic Spinal Cord Injury Hosted the 3rd Annual SCI Investor Symposium Lineage Cell Therapeutics, Inc. (NYSE American and TASE: LCTX), a clinical-stage biotechnology company developing novel allogeneic, or "off the shelf", cell therapies for serious neurological and ophthalmic conditions, today reported its second quarter 2025 financial and operating results and will

    8/12/25 4:01:00 PM ET
    $LCTX
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $LCTX
    Leadership Updates

    Live Leadership Updates

    View All

    Lineage Cell Therapeutics Announces Updates to the 3rd Annual Spinal Cord Injury Investor Symposium

    Fully Virtual Event Scheduled for June 27, 2025 Lineage Cell Therapeutics, Inc. (NYSE American and TASE: LCTX), a clinical-stage biotechnology company developing novel allogeneic, or "off the shelf", cell therapies for serious neurological and ophthalmic conditions, today announced additional presenters to the 3rd Annual Spinal Cord Injury Investor Symposium ("3rd SCIIS"). The 3rd SCIIS will be a fully virtual event, with interactive and on-demand sessions available starting on June 27, 2025. "We are excited by the incredible response by presenters that have confirmed to date and believe that our third symposium will offer attendees the most comprehensive and relevant discussions relate

    6/5/25 8:00:00 AM ET
    $LCTX
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Lineage Announces Updates to 2nd Annual Spinal Cord Injury Investor Symposium

    Persons with Lived Experience Session Expanded to Include Michaela & Kyle Devins Clinical Session Expanded to Include Neuralink Preclinical Session Expanded to Include Axonis, Novoron, Sania & Rewire Medical   Lineage Cell Therapeutics, Inc. (NYSE American and TASE: LCTX), a clinical-stage biotechnology company developing allogeneic cell therapies for unmet medical needs, today announced updates to its 2nd Annual Spinal Cord Injury Investor Symposium ("2nd SCIIS"). The 2nd SCIIS aims to accelerate development in SCI research and treatments by bringing together companies working in the development of treatments for SCI, with regulators, key opinion leaders, persons with lived exp

    5/21/24 8:00:00 AM ET
    $LCTX
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Lineage Announces Appointment of Charlotte Hubbert, Ph.D., as Vice President of Corporate Development

    Lineage Cell Therapeutics, Inc. (NYSE American and TASE: LCTX), a clinical-stage biotechnology company developing allogeneic cell therapies for unmet medical needs, today announced the appointment of veteran industry executive Charlotte Hubbert, Ph.D., as Vice President of Corporate Development. Dr. Hubbert has an extensive background in cell therapy research and venture investment across a broad range of therapeutic modalities and development stages, and has a proven ability to combine deep scientific expertise and business development acumen to identify innovative opportunities to drive both returns and impact. Dr. Hubbert previously served as Partner and Head of Gates Foundation Venture

    4/1/24 8:00:00 AM ET
    $LCTX
    $SYBX
    $VIR
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care
    Biotechnology: Pharmaceutical Preparations

    $LCTX
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    Amendment: SEC Form SC 13D/A filed by Lineage Cell Therapeutics Inc.

    SC 13D/A - Lineage Cell Therapeutics, Inc. (0000876343) (Subject)

    11/21/24 8:05:56 PM ET
    $LCTX
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    SEC Form SC 13D/A filed by Lineage Cell Therapeutics Inc. (Amendment)

    SC 13D/A - Lineage Cell Therapeutics, Inc. (0000876343) (Subject)

    2/8/24 6:57:07 PM ET
    $LCTX
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    SEC Form SC 13D/A filed by Lineage Cell Therapeutics Inc. (Amendment)

    SC 13D/A - Lineage Cell Therapeutics, Inc. (0000876343) (Subject)

    3/25/22 5:23:02 PM ET
    $LCTX
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care